Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eli Lilly
Eli Lilly
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
Thu, 02/22/18 - 11:28 pm
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Endpoints
Thu, 02/22/18 - 09:12 am
Novo Nordisk
Eli Lilly
diabetes
clinical trials
semaglutide
Trulicity
$690M deal in peril after Lilly ends mid-stage studies
Biopharma Dive
Wed, 02/21/18 - 09:43 am
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Endpoints
Mon, 02/19/18 - 11:46 am
Eli Lilly
rheumatoid arthritis
Hanmi Pharmaceutical
clinical trials
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
Xconomy
Tue, 02/13/18 - 11:02 pm
Eli Lilly
Taltz
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Endpoints
Tue, 02/13/18 - 09:45 am
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Lilly, Livongo team up for real-world diabetes research, aiming for better results in an outcomes-oriented market
Fierce Pharma
Mon, 02/12/18 - 04:31 pm
Eli Lilly
Livongo
diabetes
R&D
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Mon, 02/12/18 - 11:00 am
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity
Biopharma in charts: Key takeaways from Q4 earnings
Biopharma Dive
Mon, 02/5/18 - 12:35 pm
earnings
Merck
JNJ
AbbVie
Roche
Celgene
Eli Lilly
Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls
TheStreet.com
Sat, 02/3/18 - 09:07 am
pharma execs
M&A
earnings
drug pricing
Pfizer
Ian Read
Merck
Ken Frazier
Enrique Conterno
Eli Lilly
The Viagra effect: Sales of Lilly's ED drug Cialis slide after little blue pill goes generic
Fierce Pharma
Wed, 01/31/18 - 03:16 pm
Eli Lilly
Pfizer
erectile dysfunction
Viagra
Cialis
generics
Racing to replace opioids, biopharma is betting on pain drugs with a checkered past
Stat
Wed, 01/31/18 - 11:00 am
opioids
painkillers
NGF inhibitors
Regeneron
Pfizer
Eli Lilly
NGF blockers
Eli Lilly Cruises Through Q4 Earnings
Yahoo/24-7 Wall St
Wed, 01/31/18 - 09:21 am
Eli Lilly
earnings
Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s
Endpoints
Thu, 01/25/18 - 09:31 am
Eli Lilly
clinical trials
Alzheimer's disease
solanezumab
Senate panel approves HHS nominee Azar
Mass Device
Thu, 01/18/18 - 09:58 am
HHS
Alex Azar
Senate
Eli Lilly
Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer
Fierce Pharma
Thu, 01/11/18 - 11:56 pm
Eli Lilly
M&A
immunology
Lilly CEO: With pharma friends in high places, it's 'time for action' to ease drug costs
Fierce Pharma
Wed, 01/10/18 - 06:58 pm
Eli Lilly
Pharma CEOs
David Ricks
drug pricing
JPMHC 2018
[video]Eli Lilly CEO: It's a great time for science in pharma sector
Yahoo/CNBC
Mon, 01/8/18 - 11:28 am
Eli Lilly
Pharma CEOs
David Ricks
JPMHC 2018
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
Fri, 01/5/18 - 10:28 am
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Pfizer takes on Novartis, Lilly with Xeljanz psoriatic arthritis approval
Fierce Pharma
Fri, 12/15/17 - 11:27 pm
Pfizer
Novartis
Eli Lilly
Xeljanz
psoriatic arthritis
Pages
« first
‹ previous
…
57
58
59
60
61
62
63
64
65
…
next ›
last »